NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,569,425 | -58.2% | 97,178 | +7.5% | 0.00% | -50.0% |
| Q2 2023 | $3,751,683 | -28.8% | 90,402 | +3.2% | 0.00% | -33.3% |
| Q1 2023 | $5,267,963 | -0.2% | 87,595 | +18.7% | 0.00% | 0.0% |
| Q4 2022 | $5,277,046 | -10.8% | 73,789 | -3.9% | 0.00% | -25.0% |
| Q3 2022 | $5,913,642 | +14.4% | 76,763 | +7.5% | 0.00% | 0.0% |
| Q2 2022 | $5,167,063 | +10.5% | 71,402 | +28.3% | 0.00% | +33.3% |
| Q1 2022 | $4,677,467 | +40.5% | 55,649 | +270.6% | 0.00% | 0.0% |
| Q2 2021 | $3,330,000 | +68.3% | 15,014 | +0.3% | 0.00% | +50.0% |
| Q1 2021 | $1,979,000 | -24.3% | 14,970 | -0.9% | 0.00% | 0.0% |
| Q4 2020 | $2,613,000 | +60.6% | 15,099 | +3.3% | 0.00% | 0.0% |
| Q3 2020 | $1,627,000 | +41.0% | 14,614 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $1,154,000 | -74.5% | 14,614 | -78.3% | 0.00% | -80.0% |
| Q1 2020 | $4,528,000 | -21.9% | 67,245 | +4.7% | 0.01% | -16.7% |
| Q4 2019 | $5,798,000 | +21.0% | 64,233 | -1.5% | 0.01% | +20.0% |
| Q3 2019 | $4,790,000 | +40.2% | 65,224 | +20.7% | 0.01% | +25.0% |
| Q2 2019 | $3,416,000 | +54.2% | 54,023 | +17.4% | 0.00% | +100.0% |
| Q1 2019 | $2,216,000 | +3.3% | 46,005 | -28.2% | 0.00% | -33.3% |
| Q4 2018 | $2,145,000 | -62.9% | 64,052 | -41.9% | 0.00% | -50.0% |
| Q3 2018 | $5,779,000 | +246.7% | 110,286 | +107.0% | 0.01% | +200.0% |
| Q2 2018 | $1,667,000 | +72.2% | 53,291 | +20.0% | 0.00% | +100.0% |
| Q1 2018 | $968,000 | +6.3% | 44,411 | -1.6% | 0.00% | 0.0% |
| Q4 2017 | $911,000 | +2.1% | 45,120 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $892,000 | +11.9% | 44,980 | -2.5% | 0.00% | 0.0% |
| Q2 2017 | $797,000 | +129.7% | 46,116 | +7.6% | 0.00% | – |
| Q1 2017 | $347,000 | +20.1% | 42,850 | +16.7% | 0.00% | – |
| Q4 2016 | $289,000 | -7.7% | 36,719 | +0.2% | 0.00% | – |
| Q3 2016 | $313,000 | -24.0% | 36,633 | +3.9% | 0.00% | -100.0% |
| Q2 2016 | $412,000 | +488.6% | 35,244 | +571.7% | 0.00% | – |
| Q1 2016 | $70,000 | – | 5,247 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |